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Purpose: To compare surgical outcomes in neovascular glaucoma patients who underwent 
trabeculectomy with mitomycin C versus Ahmed Glaucoma Valve implantation. 
Patients and methods: This was a retrospective comparative case series. We reviewed 40 
eyes of 39 patients with underlying diagnosis of neovascular glaucoma, divided into two groups: 
Ahmed Glaucoma Valve (N = 20) and trabeculectomy with mitomycin C (N = 20). Surgical 
success was defined as 6 mm Hg # intraocular pressure # 21 mm Hg, with or without the 
use of glaucoma medications, with no further glaucoma surgery, and light perception or better 
vision. Early postoperative hypotony was defined as intraocular pressure , 5 mm Hg during 
the first postoperative week.
Results: The average follow-up was 31 months (range 6–87 months) for the Ahmed Glaucoma 
Valve group and 25 months (6–77 months) for the trabeculectomy group. Although the mean 
number of postoperative intraocular pressure-lowering medications was significantly higher in 
the trabeculectomy group compared with the Ahmed Glaucoma Valve group at 3 and 6 month 
time points, there was no statistically significant difference at any other time point. There was 
no statistically significant difference between both groups in postoperative visual acuity and 
intraocular pressure. Success was 70% and 65% at 1 year and 60% and 55% at 2 years after 
Ahmed Glaucoma Valve and trabeculectomy, respectively. Kaplan–Meier survival curve analysis 
showed no significant difference in success between the two groups (P = 0.815). Hyphema was 
the most common complication in both groups.
Conclusion: We found similar results after trabeculectomy with mitomycin C and Ahmed 
Glaucoma Valve implantation in eyes with neovascular glaucoma.
Keywords: glaucoma drainage implant, glaucoma filtering surgery, mitomycin C, neovascular 
glaucoma, intraocular pressure
Introduction
Neovascular glaucoma is a potentially devastating form of secondary glaucoma, which 
has a guarded visual prognosis. In the advanced stages of neovascular glaucoma, 
surgical management is often required to manage elevated intraocular pressure. 
The use of primary trabeculectomy with antifibrosis therapy and glaucoma drainage 
implant are two procedures often considered in managing patients who are refractory 
to medical therapy. Visual outcomes and surgical success for neovascular glaucoma 
patients treated with either procedure have been described.1–14 The aim of our study 
was to compare surgical outcomes after trabeculectomy with mitomycin C and the 
Ahmed Glaucoma Valve (New World Medical, Inc., Rancho Cucamonga, CA, USA) 
in patients with neovascular glaucoma.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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Material and methods
This was a single-center, retrospective, comparative study. 
The study was approved by the Institutional Review Board, 
and informed consent was obtained before the surgical 
procedures. All procedures were performed by one surgeon 
from 1998 to 2007, and all eyes in the study had at least 
6 months of postoperative follow-up. Consecutively treated 
eyes with neovascular glaucoma treated with trabeculectomy 
with mitomycin C were matched to consecutive eyes with 
neovascular glaucoma treated with the Ahmed Glaucoma 
Valve by age, race, and gender. In eyes treated with 
trabeculectomy, releasable sutures were not used; however, 
patients were treated with laser suture lysis if intraocular 
pressure was increased during the postoperative period. The 
timing of laser suture lysis and the intraoperative duration 
of exposure to mitomycin C (ranging from 2 minutes to 
4 minutes) was according to surgeon preference. During 
the study period, fewer eyes with neovascular glaucoma 
were treated with trabeculectomy with mitomycin C, and 
unmatched eyes treated with the Ahmed Glaucoma Valve 
were not included in the analysis. Exclusion criteria included 
patient age , 18 years, earlier cyclodestructive treatment, and 
earlier glaucoma drainage device implantation. Eyes in the 
trabeculectomy group with EX-PRESS® Glaucoma Filtration 
Device (Alcon, Inc., Fort Worth, TX) and eyes in both groups 
that received preoperative bevacizumab injections were not 
excluded.
Preoperative information included patient age, sex, race, 
glaucoma diagnosis, lens status, history of laser or surgical 
treatment for glaucoma, glaucoma medications, extent of 
angle closure, intraocular pressure measured by Goldmann 
applanation tonometry, and visual acuity expressed as the 
logarithm of the minimal angle of resolution (logMAR). The 
primary outcome measures were visual acuity, number of 
postoperative glaucoma medications, intraocular pressure, 
and surgical success. Postoperative data regarding intraocu-
lar pressure, medications, visual acuity, and complications 
were obtained on days 1, 7, and 15, and months 1, 3, 6, 12, 
15, 18, and 24. Results of the most recent examination were 
used for the analysis of intraocular pressure, visual acuity, 
and success at the last follow-up examination.
Criteria for success were defined before reviewing the 
data. Surgical success was defined as 6 mm Hg # intraocular 
pressure # 21 mm Hg, with or without glaucoma 
medications, without further glaucoma surgery including 
cyclophotocoagulation or complications that required 
removal of the Ahmed implant, and without loss of light 
perception. For failure due to elevated intraocular pressure, 
two consecutive visits with intraocular pressure $ 21 mm Hg 
were required. Laser suture lysis and bleb needling to 
improve bleb function were not considered failure of the 
procedure. Potential postoperative complications for either 
procedure, including hyphema, choroidal effusions, tube 
erosion, early hypotony, bleb leak, strabismus, and 
suprachoroidal hemorrhage, were assessed. Bleb leak was 
considered a complication during the late postoperative 
period (more than 6 weeks after surgery), and early hypotony 
was defined as intraocular pressure , 5 mm Hg during the 
first postoperative week.
The two groups were compared using the Mann–Whitney 
U test for continuous variables, and the χ2 and Fisher exact 
test for categorical data. Success rates in both groups were 
compared using Kaplan–Meier life table analysis and the 
log-rank test. P values of , 0.05 were considered statistically 
significant.
Results
In this study, 40 eyes of 39 patients were treated with 
standard trabeculectomy with mitomycin C (20 eyes) or the 
Ahmed Glaucoma Valve (20 eyes). One patient had bilateral 
involvement of neovascular glaucoma and had separate eyes 
included in both treatment arms. Mean ± standard deviation 
follow-up was 31.05 ± 24.45 months (range 6–87 months) 
for the trabeculectomy group and 25.00 ± 19.74 months 
(range 6–77 months) for the Ahmed Glaucoma Valve group 
(P = 0.477). The preoperative data for the two groups are 
shown in Table 1. There were no significant differences in 
sex, race, mean age, lens, status, previous glaucoma surgical 
treatment or panretinal photocoagulation, intraocular pressure, 
number of medications, etiology of neovascular glaucoma, 
extent of angle closure, or pre-existing primary open-angle 
glaucoma between the two groups. The intraoperative 
mitomycin C exposure time in the trabeculectomy group 
ranged from 2 minutes to 4 minutes at a concentration ranging 
from 0.2 mg/mL to 0.4 mg/mL. One eye in the Ahmed 
Glaucoma Valve group and two eyes in the trabeculectomy 
group received an Avastin injection prior to glaucoma surgery 
(all three were ultimately classified as failures). Two patients 
in the trabeculectomy group had an EX-PRESS Glaucoma 
Filtration Device placed during the time of surgery (neither 
was ultimately classified as a failure).
Figure 1 shows the mean logMAR vision before and after 
trabeculectomy with mitomycin C and Ahmed Glaucoma 
Valve, with no significant differences between the two 
groups. Figure 2 shows the mean intraocular pressure 
before and after surgery in both the Ahmed Glaucoma Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
283
Trabeculectomy and Ahmed glaucoma Valve in neovascular glaucoma
Valve and trabeculectomy groups. In both groups, the mean 
postoperative intraocular pressures at all follow-up time points 
were lower than the mean preoperative intraocular pressure. 
The mean intraocular pressure did not differ statistically 
between the two groups at any postoperative time point. 
Figure 3 shows the mean number of pre- and postoperative 
glaucoma medications in both groups. The trabeculectomy 
group required a statistically significantly greater number 
of postoperative medications at months 3 and 6; however, 
there was no significant difference between both groups in 
all other time points.
Kaplan–Meier survival curves following trabeculectomy 
and the Ahmed Glaucoma Valve are shown in Figure 4. 
There were no treatment failures in either group within the 
first 3 months of postoperative follow-up. The success rates 
were 90% and 85% at 6 months, 85% and 80% at 9 months, 
70% and 65% at 12 months, 70% and 60% at 15 months, 60% 
and 60% at 18 months, and 60% and 55% at 24 months in 
the Ahmed Glaucoma Valve and trabeculectomy groups, 
respectively. The numbers of patients were 20 and 20 
at 6 months, 16 and 20 after 1 year, and 14 and 19 at 
24 months after Ahmed Glaucoma Valve and trabeculectomy, 
respectively. The difference between the survival curves was 
not statistically significant (P = 0.815).
Comparisons at the last follow-up examination between the 
Ahmed Glaucoma Valve and trabeculectomy groups are shown 
in Table 2. There was no statistically significant difference 
between groups in comparisons of mean follow-up interval, 
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Figure 1 Mean logarithm of the minimal angle of resolution (logMAr) vision before 
and after trabeculectomy with mitomycin C and Ahmed glaucoma Valve (AgV). 
There were no significant differences between the two groups.
Abbreviations: D, day(s); M, month(s); Pre, preoperative.
Table 1 Preoperative characteristics of patients
Drainage  
implant 
(N = 20)
Trabeculectomy 
(N = 20)
P value
Age (y)
  Mean ± SD 54. 0 ± 15.6 59.65 ± 15.8 0.342
  range 27–88 29–88
gender (male:female) 9:11 10:10 0.752
race (AA:C) 16:4 14:6 0.465
eye (OD:OS)  12:8 11:9 0.749
Lens status 0.197
  Phakic 10 12
  Pseudophakic 3 0
  Aphakic 7 8
Preoperative Avastin
  Yes 1 2 0.549
  no 19 18
Preoperative PrP
  Yes 18 17 0.632
  no 2 3
Previous glaucoma surgery
  Yes 1 0 0.311
  no 19 20
Primary open-angle glaucoma
  Yes 7 7 1.00
  no 13 13
etiology of neovascular glaucoma
  PDr 14 13
  CrVO 3 4 0.981
  CrAO 2 2
  OiS  1 1
gonioscopy
  Open 3 4
  90° closed 0 1 0.446
  180° closed 4 2
  270° closed 0 2
  360° closed 11 11
Preoperative acuity  
(logMAr, mean ± SD)
2.11 ± 0.62 1.88 ± 0.65 0.314
Preoperative  
intraocular pressure  
(mm hg, mean ± SD)
47.7 ± 10.2 47.8 ± 11.3 0.926
Preoperative  
medications  
(mean ± SD)
3.4 ± 1.2 3.6 ± 1.1 0.603
Abbreviations:  AA,  African  American;  C,  Caucasian;  CrAO,  central  retinal 
artery occlusion; CrVO, central retinal vein occlusion; logMAr, logarithm of the 
minimal angle of resolution; OD, right eye; OiS, ocular ischemic syndrome; OS, left 
eye;  PDr,  proliferative  diabetic  retinopathy;  PrP,  panretinal  photocoagulation; 
SD, standard deviation.
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Figure 2 Mean intraocular pressure (iOP) before and after surgery in both the 
Ahmed glaucoma Valve (AgV) and trabeculectomy groups. The mean iOP did not 
differ statistically between the two groups at any postoperative time point. 
Abbreviations: D, day(s); M, month(s); Pre, preoperative.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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intraocular pressure, postoperative medications, and overall rate 
of surgical success. The success rate was 60% for the Ahmed 
Glaucoma Valve group and 55% for the trabeculectomy group 
(P = 0.474). In the Ahmed Glaucoma Valve group, a total of 
eight eyes were classified as failures: four eyes had deterioration 
of visual acuity to no light perception, two eyes developed total 
retinal detachments, one eye was enucleated secondary to no 
light perception and pain, and one eye had a final intraocular 
pressure , 5 mm Hg at the final follow-up examination. In the 
trabeculectomy group, a total of nine eyes were classified as 
failures: three eyes had deterioration of visual acuity to no 
light perception, one eye required Ahmed Glaucoma Valve 
implantation for control of intraocular pressure, one eye was 
treated with a Baerveldt Glaucoma Implant (Abbott Medical 
Optics, Santa Ana, CA) for intraocular pressure control, one 
eye required cyclophotocoagulation for intraocular pressure 
control, two eyes had intraocular pressure . 21 mm Hg at final 
examination, and one eye had intraocular pressure , 5 mm 
Hg at final examination.
Postoperative complications in both groups are summarized 
in Table 3. Hyphema was the most common complication, 
occurring in seven eyes (35%) in the Ahmed Glaucoma Valve 
group and eight eyes (40%) in the trabeculectomy group. 
One eye (5%) had choroidal effusion during the early 
postoperative period in the Ahmed Glaucoma Valve group, 
and one eye (5%) developed a suprachoroidal hemorrhage 
in the trabeculectomy group. Early postoperative hypotony 
and late wound leak occurred in the trabeculectomy group in 
two eyes (10%) and one eye (5%), respectively. There was no 
occurrence of flat anterior chamber, hypotony maculopathy, 
or endophthalmitis in either group.
Discussion
Patients with neovascular glaucoma that is refractory to 
medical and laser therapy are often managed with glaucoma 
drainage implants or trabeculectomy with antimetabolites.13,14 
Glaucoma drainage implants may be recommended as a 
primary surgical procedure in patients with neovascular 
glaucoma, especially in eyes with severe inflammation 
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Figure  3  Mean  number  of  pre-  and  postoperative  glaucoma  medications  after 
Ahmed glaucoma Valve (AgV) and trabeculectomy. The trabeculectomy group 
required  a  statistically  significantly  greater  number  of  glaucoma  medications  at 
months 3 and 6 (asterisks); however, there was no significant difference between 
both groups in all other time points. 
Abbreviations: D, day(s); M, month(s); Pre, preoperative.
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Figure  4  Kaplan–Meier  survival  curves  following  trabeculectomy  and  Ahmed 
glaucoma Valve (AgV). The success rates were 70% and 65% at 12 months, and 
60% and 55% at 24 months in the AgV and trabeculectomy groups, respectively. The 
difference between the survival curves was not statistically significant (P = 0.815).
Table 2 Last follow-up examination
Drainage  
implant 
(N = 20)
Trabeculectomy 
(N = 20)
P value
Follow-up interval  
(months, mean ± SD)
31.1 ± 24.5 25.0 ± 19.7 0.477
Visual acuity  
(logMAr, mean ± SD)
2.6 ± 0.3 2.0 ± 0.8 0.011a
Postoperative  
intraocular pressure  
(mm hg, mean ± SD)
13.7 ± 13.1 16.5 ± 10.9 0.289
Postoperative medications  
(mean ± SD)
1.0 ± 1.5 1.8 ± 1.7 0.150
Surgical outcome
  Success 12 (60%) 11 (55%) 0.474
  Failure 8 (40%) 9 (45%)
Note: aP , 0.05.
Abbreviations: logMAr, logarithm of the minimal angle of resolution; SD, standard 
deviation.
Table 3 Complications
Drainage implant 
(N = 20)
Trabeculectomy 
(N = 20)
hyphema 7 8
Choroidal effusion 1 0
Suprachoroidal  
hemorrhage
0 1
early hypotonya 0 2
Late wound leak 0 1
endophthalmitis 0 0
Total number of  
complicationsb
8 12
Notes:  aEarly  hypotony  defined  as  intraocular  pressure  ,  5  mm  hg  during 
the  first  postoperative  week;  bNo  significant  differences  by  comparison  of 
proportions (z) test.Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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at presentation.15,16 However, trabeculectomy with antifibrosis 
drugs such as mitomycin C may be an appropriate procedure 
for neovascular glaucoma.17 In this study, we found similar 
surgical outcomes in patients with neovascular glaucoma 
treated with the Ahmed Glaucoma Valve or trabeculectomy 
with mitomycin C.
In a previous study of trabeculectomy with mitomycin C 
in 24 eyes with neovascular glaucoma, Hyung and Kim18 
found a surgical success rate of 71% at 1 month and 29% at 
1 year after surgery. In 15 eyes with neovascular glaucoma 
treated with trabeculectomy with mitomycin C, Mandal et al11 
had a higher success rate of 66.7% at 1 year after surgery, 
which is comparable with the results in our trabeculectomy 
group (65%). After Ahmed Glaucoma Valve implantation 
in 38 eyes with neovascular glaucoma, Yalvac et al12 had 
a surgical success rate of 63.3% at 1 year, which was 
comparable with the success rate at 1 year after Ahmed 
Glaucoma Valve implantation in our study (70%). Im et al10 
directly compared treatment with both Ahmed Glaucoma 
Valve and trabeculectomy with mitomycin C, with complete 
success defined as intraocular pressure , 21 mm Hg without 
medication, and qualified success as ,21 mm Hg with 
medication. At 1 year after trabeculectomy and Ahmed 
Glaucoma Valve implantation, complete success was 47.8% 
and 42.3% and qualified success was 30.4% and 46.2%, 
respectively. Our success rates may have been higher due 
to differences in inclusion and exclusion criteria or other 
variables. Despite having lower surgical success rates at 
1 year after surgery, there was no statistical difference 
between both groups, consistent with our findings.
In our study, despite control of intraocular pressure after 
the procedure, three patients in the trabeculectomy group 
and six patients in the Ahmed Glaucoma Valve group lost 
light perception vision. This has been described previously 
in neovascular glaucoma patients and has been attributed 
to possible progression of the underlying disease.7,14,19–21 
Use of antivascular endothelial growth factor (anti-VEGF) 
drugs may improve outcomes after glaucoma surgery in eyes 
with neovascular glaucoma.22,23 In eyes with neovascular 
glaucoma, Lupinacci et al24 found improved visual outcomes 
and reduced need for glaucoma surgery after intravitreal 
bevacizumab treatment, although eyes with closed angles 
required surgery despite anti-VEGF treatment. Although 
only a single case in the Ahmed Glaucoma Valve group and 
two cases in the trabeculectomy group received an intravitreal 
bevacizumab injection in the preoperative period, all three 
cases were ultimately classified as failures based on the 
criteria in this study, possibly due to advanced disease at the 
time of presentation. Although the EX-PRESS implantation 
has similar long-term success compared with trabeculectomy 
in other types of glaucoma,25 the number of patients with 
the EX-PRESS implant (two) was too low to detect any 
influence on success in neovascular glaucoma or potential 
bias of the study.
The nonrandomized retrospective design of this study 
has potential sources of bias. To minimize any bias, patients 
in each group were matched based on age, sex, and race. 
No major differences were observed in the preoperative 
characteristics of the patients, including the preoperative 
vision and the extent of angle closure. Nonetheless, patients 
treated with cyclophotocoagulation or other drainage implants 
were excluded from the study, and surgeon preference 
determined whether the patient was treated with the Ahmed 
Glaucoma Valve or trabeculectomy. Thus, the possibility of 
investigator bias exists in this study, including the possibility 
that patients were selected for either procedure based on 
criteria not measured in this study. Also, the sample size was 
small, introducing the possibility of a type II (false negative) 
statistical error. Our study did not evaluate the surgical 
outcomes after prior vitrectomy, which has been identified as 
a prognostic factor for surgical failure for trabeculectomy26 
but not for the Ahmed Glaucoma Valve.27 Our assessment 
of the number of complications after trabeculectomy was 
likely low because we did not include early bleb leaks and 
bleb needling as complications. An advantage of this study 
was the follow-up period being, on average, over 2 years, 
which is relatively long compared with other studies of 
neovascular glaucoma patients, due to increased mortality 
and poor compliance with follow-up due to other systemic 
comorbidities.28,29
Conclusion
We found similar intraocular pressure reduction and surgical 
success after use of Ahmed Glaucoma Valve and trabeculectomy 
with mitomycin C in the treatment of neovascular glaucoma. 
Hyphema was the most common postoperative complication 
encountered in both groups, and other complications were 
relatively uncommon. Although success rates decline over 
time after either procedure, both Ahmed Glaucoma Valve 
and trabeculectomy with mitomycin C may be useful in the 
treatment of neovascular glaucoma that is refractory to medical 
and laser therapy.
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